Nine statements about substance interactions from William E. White’s DXM FAQ, with current clarifications. Each comparison starts with the current interpretation, followed by a historical paraphrase.
Current clarifications
MDMA, MDA and 2C-B
Current clarification
Interaction mechanisms differ among substances within a chemical class. MDMA has direct pharmacokinetic interaction data.
Historical statement · paraphrase
MDMA, MDA, and 2C-B grouped as phenethylamines
Opioids
Current clarification
Separate respiratory and serotonergic mechanisms
Historical statement · paraphrase
Opioids treated as one class
Ketamine
Current clarification
Inadequate explanation; quantitative interaction remains poorly studied
Historical statement · paraphrase
Ketamine largely displaces DXM effects because of a shared binding site
Nitrous oxide (N₂O)
Current clarification
Subjective potentiation is plausible; absence of physical hazard is not established
Historical statement · paraphrase
N2O potentiates DXM without additional adverse effects
Ethanol and NMDA
Current clarification
No clinical basis to regard them as prevention of injury
Historical statement · paraphrase
Ethanol or other agents protect against presumed NMDA-related neurotoxicity
Yohimbine
Current clarification
Such injury is not established in humans; assess autonomic stress instead
Historical statement · paraphrase
Yohimbine produces Olney’s lesions with DXM
Nicotine and tobacco smoke
Current clarification
Nicotine and tobacco smoke differ. Reduced MAO activity has been described in smokers; prescribed MAOI exposure occurs under different conditions.
Historical statement · paraphrase
Cigarettes can be treated as nicotine or as a conventional MAOI
Sedating antihistamines
Current clarification
Consider chlorphenamine’s SERT effects, sedation, anticholinergic effects, and possible CYP inhibition
Historical statement · paraphrase
Sedating antihistamines are neutral additions
Subjective tolerability
Current clarification
It does not exclude hyperthermia, arrhythmias, aspiration, or altered exposure
Historical statement · paraphrase
Good subjective tolerability establishes safety
Reassessing FAQ statements
This review reassesses the interaction claims in William E. White’s *The Dextromethorphan FAQ*, Text Version 4.0 (1997), particularly Section 13 [1], against human studies, prescribing information, clinical reports, and scientific reviews. Targeted searches of accessible scientific and regulatory sources were conducted on 2 October 2026. Topics included CYP2D6, MDMA, serotonin toxicity, opioids, cannabinoids, MAOIs, antihistamines, and other dissociatives.
The historical Olney's lesions hypothesis
The Olney’s lesions hypothesis belongs to the historical discussion. The grounds for numerical ratings are given in the individual combination descriptions. Injury during severe intoxication is a broader question than this hypothesis.
An example: chemical classification and interaction
Interaction mechanisms differ among substances within a chemical class. MDMA has direct pharmacokinetic interaction data.
Comparison summary
Historical explanations and current evidential grounds can differ.
Sources
- 2. Sources and methods
- 10. Reassessing historical FAQ claims
- Olney’s lesions and limits of the conclusions
- Historical claim: “MDMA, MDA, and 2C-B grouped as phenethylamines”
- Historical claim: “Opioids treated as one class”
- Historical claim: “Ketamine largely displaces DXM effects because of a shared binding site”
- Historical claim: “N2O potentiates DXM without additional adverse effects”
- Historical claim: “Ethanol or other agents protect against presumed NMDA-related neurotoxicity”
- Historical claim: “Yohimbine produces Olney’s lesions with DXM”
- Historical claim: “Cigarettes can be treated as nicotine or as a conventional MAOI”
- Historical claim: “Sedating antihistamines are neutral additions”
- Historical claim: “Good subjective tolerability establishes safety”